NCT06748872View on ClinicalTrials.gov

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

August 1, 2042

Conditions
Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)Myxoid LiposarcomaSynovial Sarcoma
Interventions
DRUG

Lymphodepletion

Cylcophosamide and Fludarabine

BIOLOGICAL

TCR-T cells (MDG1015)

TCR-T cells (MDG1015)

Trial Locations (1)

98109

Fred Hutch Cancer Center, Seattle

Sponsors

Lead Sponsor

Medigene AG
All Listed Sponsors
lead

Medigene AG

INDUSTRY

NCT06748872 - EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma | Biotech Hunter | Biotech Hunter